NYSE:GKOS Glaukos (GKOS) Stock Forecast, Price & News $68.26 +1.71 (+2.57%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$65.52▼$70.0550-Day Range$45.44▼$68.2652-Week Range$40.45▼$70.05Volume809,275 shsAverage Volume421,540 shsMarket Capitalization$3.29 billionP/E RatioN/ADividend YieldN/APrice Target$61.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Glaukos MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside9.7% Downside$61.67 Price TargetShort InterestBearish11.89% of Float Sold ShortDividend StrengthN/ASustainability-0.90Upright™ Environmental ScoreNews Sentiment0.25Based on 25 Articles This WeekInsider TradingSelling Shares$2.10 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.30) to ($1.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.45 out of 5 starsMedical Sector916th out of 986 stocksSurgical & Medical Instruments Industry89th out of 97 stocks 1.3 Analyst's Opinion Consensus RatingGlaukos has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $61.67, Glaukos has a forecasted downside of 9.7% from its current price of $68.26.Amount of Analyst CoverageGlaukos has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.89% of the float of Glaukos has been sold short.Short Interest Ratio / Days to CoverGlaukos has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.Change versus previous monthShort interest in Glaukos has recently increased by 7.66%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlaukos does not currently pay a dividend.Dividend GrowthGlaukos does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlaukos has received a 65.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical laser systems", "Medical technology engineering", and "Surgical instruments" products. See details.Environmental SustainabilityThe Environmental Impact score for Glaukos is -0.90. Previous Next 2.4 News and Social Media Coverage News SentimentGlaukos has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Glaukos this week, compared to 4 articles on an average week.MarketBeat Follows2 people have added Glaukos to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Glaukos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,100,990.00 in company stock.Percentage Held by InsidersOnly 7.80% of the stock of Glaukos is held by insiders.Percentage Held by Institutions92.17% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Glaukos are expected to grow in the coming year, from ($2.30) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Glaukos is -23.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Glaukos is -23.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlaukos has a P/B Ratio of 6.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Glaukos (NYSE:GKOS) StockGlaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.Read More Receive GKOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter. Email Address GKOS Stock News HeadlinesJune 8, 2023 | finance.yahoo.com4 big analyst picks: Wall Street extols AmazonJune 8, 2023 | msn.com4 big analyst picks: Amazon earns an upgrade and a coverage initiationJune 9, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Develops World's First Anti-Aircraft LaserSmall cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>June 7, 2023 | msn.comGlaukos upgraded to overweight by Piper Sandler ahead of product launchesJune 7, 2023 | markets.businessinsider.comGlaukos Poised for $1B in Sales by 2030: Piper Sandler Predicts With Stock UpgradeJune 7, 2023 | msn.comBenzinga's Top Ratings Upgrades, Downgrades For June 7, 2023June 7, 2023 | cnbc.comThis medtech stock has a 'pathway to $1B in sales' by 2030, Piper Sandler saysJune 7, 2023 | msn.comPiper Sandler Upgrades Glaukos (GKOS)June 9, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!June 7, 2023 | americanbankingnews.comGlaukos (NYSE:GKOS) Raised to Overweight at Piper SandlerJune 7, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Paratek Pharmaceuticals (PRTK), Glaukos (GKOS) and Ionis Pharmaceuticals (IONS)June 7, 2023 | americanbankingnews.comBTIG Research Increases Glaukos (NYSE:GKOS) Price Target to $67.00June 5, 2023 | msn.comBTIG Maintains Glaukos (GKOS) Buy RecommendationJune 5, 2023 | msn.comWells Fargo Maintains Glaukos (GKOS) Equal-Weight RecommendationJune 5, 2023 | markets.businessinsider.comAnalyst Expectations for Glaukos's FutureJune 5, 2023 | americanbankingnews.comGlaukos (NYSE:GKOS) Price Target Raised to $63.00June 5, 2023 | finance.yahoo.comGlaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)June 2, 2023 | americanbankingnews.comBrokerages Set Glaukos Co. (NYSE:GKOS) Price Target at $56.13June 2, 2023 | americanbankingnews.comGlaukos (NYSE:GKOS) Rating Lowered to Sell at StockNews.comMay 31, 2023 | americanbankingnews.comGlaukos Co. (NYSE:GKOS) Sees Significant Growth in Short InterestMay 28, 2023 | finance.yahoo.comDespite currently being unprofitable, Glaukos (NYSE:GKOS) has delivered a 43% return to shareholders over 5 yearsMay 22, 2023 | americanbankingnews.comGlaukos Co. (NYSE:GKOS) CEO Sells $701,702.54 in StockMay 20, 2023 | americanbankingnews.comGlaukos Co. (NYSE:GKOS) CEO Sells $222,277.04 in StockMay 10, 2023 | nasdaq.comGKOS Crosses Above Average Analyst TargetMay 10, 2023 | msn.comStephens & Co. Reiterates Glaukos (GKOS) Overweight RecommendationMay 8, 2023 | americanbankingnews.comAnalysts Set Glaukos Co. (NYSE:GKOS) Price Target at $56.13May 8, 2023 | americanbankingnews.com888 Reiterates Maintains Rating for Glaukos (NYSE:GKOS)See More Headlines GKOS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GKOS Company Calendar Last Earnings5/03/2023Today6/08/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:GKOS CUSIPN/A CIK1192448 Webwww.glaukos.com Phone(949) 367-9600Fax949-367-9984Employees727Year FoundedN/APrice Target and Rating Average Stock Price Forecast$61.67 High Stock Price Forecast$80.00 Low Stock Price Forecast$48.00 Forecasted Upside/Downside-9.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-99,190,000.00 Net Margins-48.15% Pretax Margin-47.86% Return on Equity-21.20% Return on Assets-11.35% Debt Debt-to-Equity Ratio0.70 Current Ratio6.67 Quick Ratio6.02 Sales & Book Value Annual Sales$282.86 million Price / Sales11.63 Cash FlowN/A Price / Cash FlowN/A Book Value$11.11 per share Price / Book6.14Miscellaneous Outstanding Shares48,210,000Free Float44,449,000Market Cap$3.29 billion OptionableOptionable Beta1.23 Key ExecutivesThomas William BurnsChairman & Chief Executive OfficerJoseph E. GilliamPresident & Chief Operating OfficerAlex ThurmanChief Financial Officer & Senior Vice PresidentJay L. KatzChief Medical OfficerDiane W. BiagiantiSenior Vice President & General CounselKey CompetitorsiRhythm TechnologiesNASDAQ:IRTCIntegra LifeSciencesNASDAQ:IARTInari MedicalNASDAQ:NARIAxonicsNASDAQ:AXNXAtriCureNASDAQ:ATRCView All CompetitorsInsiders & InstitutionsThomas William BurnsSold 17,382 sharesTotal: $1.17 M ($67.20/share)Thomas William BurnsSold 142 sharesTotal: $8,520.00 ($60.00/share)Macquarie Group Ltd.Bought 9,046 shares on 6/1/2023Ownership: 0.065%Thomas William BurnsSold 7 sharesTotal: $420.00 ($60.00/share)Ameriprise Financial Inc.Sold 6,200 shares on 5/22/2023Ownership: 0.370%View All Insider TransactionsView All Institutional Transactions GKOS Stock - Frequently Asked Questions Should I buy or sell Glaukos stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GKOS shares. View GKOS analyst ratings or view top-rated stocks. What is Glaukos' stock price forecast for 2023? 9 equities research analysts have issued 12 month price targets for Glaukos' shares. Their GKOS share price forecasts range from $48.00 to $80.00. On average, they predict the company's share price to reach $61.67 in the next year. This suggests that the stock has a possible downside of 9.7%. View analysts price targets for GKOS or view top-rated stocks among Wall Street analysts. How have GKOS shares performed in 2023? Glaukos' stock was trading at $43.68 at the start of the year. Since then, GKOS shares have increased by 56.3% and is now trading at $68.26. View the best growth stocks for 2023 here. Are investors shorting Glaukos? Glaukos saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 5,480,000 shares, an increase of 7.7% from the April 30th total of 5,090,000 shares. Based on an average trading volume of 408,400 shares, the days-to-cover ratio is currently 13.4 days. Approximately 11.9% of the company's stock are sold short. View Glaukos' Short Interest. When is Glaukos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our GKOS earnings forecast. How were Glaukos' earnings last quarter? Glaukos Co. (NYSE:GKOS) issued its earnings results on Wednesday, May, 3rd. The medical instruments supplier reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.61) by $0.02. The medical instruments supplier earned $73.90 million during the quarter, compared to the consensus estimate of $67.74 million. Glaukos had a negative trailing twelve-month return on equity of 21.20% and a negative net margin of 48.15%. Glaukos's revenue was up 9.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.38) EPS. What ETFs hold Glaukos' stock? ETFs with the largest weight of Glaukos (NYSE:GKOS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Principal Healthcare Innovators ETF (BTEC), SPDR S&P SmallCap 600 ESG ETF (ESIX), Xtrackers S&P SmallCap 600 ESG ETF (SMLE), iShares S&P Small-Cap 600 Growth ETF (IJT), SPDR S&P 600 Small Cap Growth ETF (SLYG) and Vanguard S&P Small-Cap 600 Growth ETF (VIOG). What guidance has Glaukos issued on next quarter's earnings? Glaukos issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $295.00 million-$300.00 million, compared to the consensus revenue estimate of $293.53 million. What is Thomas W. Burns' approval rating as Glaukos' CEO? 10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Glaukos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA). When did Glaukos IPO? (GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers. What is Glaukos' stock symbol? Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS." Who are Glaukos' major shareholders? Glaukos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (9.72%), Brown Capital Management LLC (6.03%), Artisan Partners Limited Partnership (3.89%), Braidwell LP (3.75%), State Street Corp (3.63%) and Fred Alger Management LLC (3.15%). Insiders that own company stock include Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link. View institutional ownership trends. How do I buy shares of Glaukos? Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Glaukos' stock price today? One share of GKOS stock can currently be purchased for approximately $68.26. How much money does Glaukos make? Glaukos (NYSE:GKOS) has a market capitalization of $3.29 billion and generates $282.86 million in revenue each year. The medical instruments supplier earns $-99,190,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. How many employees does Glaukos have? The company employs 727 workers across the globe. How can I contact Glaukos? Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for the company is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at investors@glaukos.com, or via fax at 949-367-9984. This page (NYSE:GKOS) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Glaukos Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.